{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:53:19Z","timestamp":1788940399453,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.metabol.2014.07.017","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T12:18:20Z","timestamp":1407845900000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Leptin in congenital and HIV-associated lipodystrophy"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-7274","authenticated-orcid":false,"given":"Michael A.","family":"Tsoukas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0005","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0010","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1074\/jbc.275.12.8456","article-title":"Mechanism of insulin resistance in a-zip\/f-1 fatless mice","volume":"275","author":"Kim","year":"2000","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0015","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.ijo.0803025","article-title":"Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis","volume":"29","author":"Ceddia","year":"2005","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0020","doi-asserted-by":"crossref","first-page":"E567","DOI":"10.1152\/ajpendo.00315.2011","article-title":"Leptin in human physiology and pathophysiology","volume":"301","author":"Mantzoros","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0025","first-page":"2583","article-title":"Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli","volume":"118","author":"Rosenbaum","year":"2008","journal-title":"J Clin Invest"},{"issue":"5843","key":"10.1016\/j.metabol.2014.07.017_bb0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1144599","article-title":"Leptin regulates striatal regions and human eating behavior","volume":"317","author":"Farooqi","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3945\/ajcn.111.012385","article-title":"Leptin reverses declines in satiation in weight-reduced obese humans","volume":"95","author":"Kissileff","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0040","doi-asserted-by":"crossref","first-page":"e59114","DOI":"10.1371\/journal.pone.0059114","article-title":"Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans","volume":"8","author":"Hinkle","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0045","doi-asserted-by":"crossref","first-page":"991s","DOI":"10.3945\/ajcn.2008.26788E","article-title":"Leptin in humans: lessons from translational research","volume":"89","author":"Bluher","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0050","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1210\/en.2008-0498","article-title":"Leptin regulates peripheral lipid metabolism primarily through central effects on food intake","volume":"149","author":"Prieur","year":"2008","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2337\/diab.47.2.230","article-title":"Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin a mice despite suppression of hypothalamic neuropeptide y and circulating corticosterone concentrations","volume":"47","author":"Mantzoros","year":"1998","journal-title":"Diabetes"},{"issue":"Pt 1","key":"10.1016\/j.metabol.2014.07.017_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1042\/bst0310196","article-title":"Role of amp-activated protein kinase in leptin-induced fatty acid oxidation in muscle","volume":"31","author":"Minokoshi","year":"2003","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0070","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1152\/ajpendo.00146.2011","article-title":"Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women","volume":"301","author":"Brinkoetter","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology: emerging clinical applications","volume":"152","author":"Kelesidis","year":"2010","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0080","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2337\/diabetes.51.7.2105","article-title":"Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans","volume":"51","author":"Chan","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2014.07.017_bb0085","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MED.0b013e3282f1cfdc","article-title":"Leptin in reproduction","volume":"14","author":"Bluher","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0095","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2004-2232","article-title":"Independent circadian and sleep\/wake regulation of adipokines and glucose in humans","volume":"90","author":"Shea","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0100","first-page":"2856","article-title":"Effect of birth weight and maternal smoking on cord blood leptin concentrations of full-term and preterm newborns","volume":"82","author":"Mantzoros","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4000418","article-title":"Leptin in relation to resumption of menses in women with anorexia nervosa","volume":"3","author":"Audi","year":"1998","journal-title":"Mol Psychiatry"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0110","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/diab.45.11.1638","article-title":"Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity","volume":"45","author":"Houseknecht","year":"1996","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0115","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/diabetes.51.5.1337","article-title":"Effects of acute and chronic administration of the melanocortin agonist mtii in mice with diet-induced obesity","volume":"51","author":"Pierroz","year":"2002","journal-title":"Diabetes"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2014.07.017_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1012947113197","article-title":"Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis","volume":"4","author":"Chan","year":"2001","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.yfrne.2010.06.002","article-title":"Leptin in human physiology and therapeutics","volume":"31","author":"Dardeno","year":"2010","journal-title":"Front Neuroendocrinol"},{"issue":"5223","key":"10.1016\/j.metabol.2014.07.017_bb0130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.7624776","article-title":"Effects of the obese gene product on body weight regulation in ob\/ob mice","volume":"269","author":"Pelleymounter","year":"1995","journal-title":"Science"},{"issue":"5223","key":"10.1016\/j.metabol.2014.07.017_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"issue":"5223","key":"10.1016\/j.metabol.2014.07.017_bb0140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1126\/science.7624778","article-title":"Recombinant mouse ob protein: evidence for a peripheral signal linking adiposity and central neural networks","volume":"269","author":"Campfield","year":"1995","journal-title":"Science"},{"issue":"9479","key":"10.1016\/j.metabol.2014.07.017_bb0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(05)66830-4","article-title":"Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa","volume":"366","author":"Chan","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0150","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/367859","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.metabol.2014.07.017_bb0155","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0160","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0165","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc10-0518","article-title":"Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans","volume":"34","author":"Moon","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jocd.2010.08.002","article-title":"The pilot study of DXA assessment in Chinese HIV-infected men with clinical lipodystrophy","volume":"14","author":"Yao","year":"2011","journal-title":"J Clin Densitom"},{"issue":"9311","key":"10.1016\/j.metabol.2014.07.017_bb0180","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor srebp1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0185","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1043-2760(00)00309-X","article-title":"Lipoatrophy revisited","volume":"11","author":"Reitman","year":"2000","journal-title":"Trends Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.metabol.2014.07.017_bb0190","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/00002030-199911120-00008","article-title":"Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy","volume":"13","author":"Domingo","year":"1999","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0195","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/jc.2009-0340","article-title":"Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?","volume":"94","author":"Mantzoros","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0200","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ecl.2004.03.003","article-title":"Lipodystrophies: rare disorders causing metabolic syndrome","volume":"33","author":"Garg","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0210","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg.39.10.722","article-title":"Genotype\u2013phenotype relationships in Berardinelli\u2013Seip congenital lipodystrophy","volume":"39","author":"Van Maldergem","year":"2002","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0215","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1210\/jc.2003-030855","article-title":"Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy","volume":"88","author":"Agarwal","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0220","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbalip.2008.12.014","article-title":"Lipodystrophies: disorders of adipose tissue biology","volume":"1791","author":"Garg","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0225","first-page":"358","article-title":"Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy","volume":"75","author":"Garg","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0230","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1210\/jc.2003-030835","article-title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the agpat2 or seipin genes","volume":"88","author":"Simha","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0235","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.metabol.2014.07.017_bb0240","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/ajmg.a.32457","article-title":"Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability","volume":"146a","author":"Simha","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0245","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-69-3-501","article-title":"Congenital generalized lipodystrophy accompanied by cystic angiomatosis","volume":"69","author":"Brunzell","year":"1968","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00241817","article-title":"The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy","volume":"21","author":"Fleckenstein","year":"1992","journal-title":"Skeletal Radiol"},{"issue":"7715","key":"10.1016\/j.metabol.2014.07.017_bb0255","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(71)92085-X","article-title":"Bone lesions in congenital generalised lipodystrophy","volume":"2","author":"Guell-Gonzalez","year":"1971","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1399-0004.2002.610407.x","article-title":"Cardiomyopathy in congenital complete lipodystrophy","volume":"61","author":"Bhayana","year":"2002","journal-title":"Clin Genet"},{"key":"10.1016\/j.metabol.2014.07.017_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1651-2227.1996.tb14264.x","article-title":"Cardiac findings in generalized lipodystrophy","volume":"413","author":"Bjornstad","year":"1996","journal-title":"Acta Paediatr Suppl"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0270","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3476(86)80389-4","article-title":"Hypertrophic cardiomyopathy in total lipodystrophy","volume":"109","author":"Rheuban","year":"1986","journal-title":"J Pediatr"},{"issue":"13","key":"10.1016\/j.metabol.2014.07.017_bb0275","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0280","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","article-title":"Clinical review 159: human immunodeficiency virus\/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"9170","key":"10.1016\/j.metabol.2014.07.017_bb0285","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0290","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","article-title":"Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy","volume":"13","author":"Gervasoni","year":"1999","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0295","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QAI.0b013e3181aa1308","article-title":"The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy","volume":"51","author":"Shlay","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0300","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1473-3099(07)70287-6","article-title":"Hiv-associated dyslipidaemia: pathogenesis and treatment","volume":"7","author":"Oh","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"10.1016\/j.metabol.2014.07.017_bb0305","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1097\/00002030-200011100-00001","article-title":"Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors","volume":"14","author":"Maggi","year":"2000","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00002030-200102160-00005","article-title":"Premature atherosclerosis in HIV-infected individuals\u2014focus on protease inhibitor therapy","volume":"15","author":"Depairon","year":"2001","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0315","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0021-9150(01)00736-5","article-title":"Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors","volume":"162","author":"Seminari","year":"2002","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0325","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0330","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (d:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0335","first-page":"89","article-title":"Hiv-associated lipodystrophy, metabolic complications, and antiretroviral toxicities","volume":"3","author":"Moyle","year":"2002","journal-title":"HIV Clin Trials"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0340","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0345","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch Intern Med"},{"issue":"13","key":"10.1016\/j.metabol.2014.07.017_bb0350","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.metabol.2014.07.017_bb0355","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/QAD.0b013e3280adc91e","article-title":"The role of adipokines in relation to HIV lipodystrophy","volume":"21","author":"Sweeney","year":"2007","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0360","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1053\/meta.2002.34704","article-title":"Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy","volume":"51","author":"Hadigan","year":"2002","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0365","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3844\/ajidsp.2006.141.152","article-title":"Leptin and adiponectin in the HIV associated metabolic syndrome: physiologic and therapeutic implications","volume":"2","author":"Tsiodras","year":"2006","journal-title":"Am J Infect Dis"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0370","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbalip.2009.09.018","article-title":"Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment","volume":"1801","author":"Villarroya","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0375","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.metabol.2010.09.011","article-title":"Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0380","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkn251","article-title":"Hiv-associated lipodystrophy a review of underlying mechanisms and therapeutic options","volume":"62","author":"Mallewa","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"15","key":"10.1016\/j.metabol.2014.07.017_bb0385","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1074\/jbc.M312875200","article-title":"In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3t3 and human preadipocytes or adipocytes","volume":"279","author":"El Hadri","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0390","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jac\/dkn191","article-title":"The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy","volume":"62","author":"Perez-Molina","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0395","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0400","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.23647","article-title":"Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells","volume":"52","author":"Blas-Garcia","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0405","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.metabol.2004.08.022","article-title":"Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy","volume":"54","author":"Chaparro","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0410","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0415","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/me.2007-0124","article-title":"Human immunodeficiency virus (HIV)-1 viral protein r suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy","volume":"22","author":"Shrivastav","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00126334-200107010-00005","article-title":"Association between insulin resistance and hepatitis c virus chronic infection in HIV-hepatitis c virus-coinfected patients undergoing antiretroviral therapy","volume":"27","author":"Duong","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0425","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.metabol.2009.04.021","article-title":"Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy","volume":"58","author":"Han","year":"2009","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0430","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.metabol.2009.04.011","article-title":"Obesity and lymphocyte subsets in virologically suppressed HIV-infected patients","volume":"58","author":"Adeyemi","year":"2009","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0435","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.metabol.2009.02.026","article-title":"Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients","volume":"58","author":"Rossi","year":"2009","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0440","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.metabol.2005.08.018","article-title":"Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy","volume":"55","author":"Haugaard","year":"2006","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0445","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1086\/430379","article-title":"Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women","volume":"40","author":"Jacobson","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0450","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1086\/375225","article-title":"Exercise and vitamin e intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study","volume":"36","author":"Gavrila","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0455","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0b013e3282f33557","article-title":"Zidovudine\/lamivudine contributes to insulin resistance within 3months of starting combination antiretroviral therapy","volume":"22","author":"Blumer","year":"2008","journal-title":"AIDS"},{"issue":"6869","key":"10.1016\/j.metabol.2014.07.017_bb0460","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating amp-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0465","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1073\/pnas.0909422107","article-title":"Leptin therapy in insulin-deficient type I diabetes","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0470","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11883-000-0077-1","article-title":"Mouse models of lipodystrophy","volume":"2","author":"Reue","year":"2000","journal-title":"Curr Atheroscler Rep"},{"issue":"6748","key":"10.1016\/j.metabol.2014.07.017_bb0475","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"issue":"6772","key":"10.1016\/j.metabol.2014.07.017_bb0480","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/35002663","article-title":"Leptin and diabetes in lipoatrophic mice","volume":"403","author":"Gavrilova","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0485","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diabetes.50.6.1440","article-title":"Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes","volume":"50","author":"Ebihara","year":"2001","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0490","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.2007.03095.x","article-title":"Leptin therapy for partial lipodystrophy linked to a ppar-gamma mutation","volume":"68","author":"Guettier","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0495","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0500","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0505","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0510","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM200408053510623","article-title":"Long-term leptin-replacement therapy for lipoatrophic diabetes","volume":"351","author":"Ebihara","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0515","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0520","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0525","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0530","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1210\/en.2007-0754","article-title":"Long-term effects of central leptin and resistin on body weight, insulin resistance, and beta-cell function and mass by the modulation of hypothalamic leptin and insulin signaling","volume":"149","author":"Park","year":"2008","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0535","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1096\/fj.07-101824","article-title":"Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-jun n-terminal kinases","volume":"22","author":"Maedler","year":"2008","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0540","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/jcem.83.9.5143","article-title":"Clinical review 97: syndromes of severe insulin resistance","volume":"83","author":"Tritos","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0545","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diacare.26.1.30","article-title":"Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy","volume":"26","author":"Simha","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0555","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jc.2003-031868","article-title":"Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency","volume":"89","author":"McDuffie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0560","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0565","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0570","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0575","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.300.5.509","article-title":"Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial","volume":"300","author":"Lo","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0580","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1530\/eje.1.02039","article-title":"Gh treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study","volume":"153","author":"Luzi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0585","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00125-009-1545-y","article-title":"Leptin therapy in lipodystrophy","volume":"53","author":"Savage","year":"2010","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1016\/j.metabol.2014.07.017_bb0595","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.2337\/diabetes.54.suppl_2.S108","article-title":"Mechanisms of beta-cell death in type 2 diabetes","volume":"54","author":"Donath","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0600","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study","volume":"16","author":"Noor","year":"2002","journal-title":"AIDS"},{"issue":"16","key":"10.1016\/j.metabol.2014.07.017_bb0605","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0610","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.metabol.2012.03.013","article-title":"Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome","volume":"61","author":"Sekhar","year":"2012","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0615","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.metabol.2013.09.003","article-title":"Advances in metabolism","volume":"62","author":"Tsoukas","year":"2013","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-08-0597","article-title":"R-methuleptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating igf and igf-binding protein levels: observational and interventional studies in humans","volume":"160","author":"Brennan","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"22","key":"10.1016\/j.metabol.2014.07.017_bb0625","doi-asserted-by":"crossref","first-page":"8481","DOI":"10.1073\/pnas.0505429103","article-title":"Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans","volume":"103","author":"Chan","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6704","key":"10.1016\/j.metabol.2014.07.017_bb0630","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0635","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1210\/jc.2009-2502","article-title":"Effects of insulin-like growth factor (IGF)-i\/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance","volume":"95","author":"Rao","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.metabol.2014.07.017_bb0640","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-199910220-00013","article-title":"Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV","volume":"13","author":"Wanke","year":"1999","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0645","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","article-title":"The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients","volume":"54","author":"Musso","year":"2005","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0650","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0655","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1210\/jc.2002-020792","article-title":"Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy","volume":"87","author":"Simha","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2014.07.017_bb0660","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40265-013-0074-7","article-title":"Metreleptin: first global approval","volume":"73","author":"Chou","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2014.07.017_bb0665","article-title":"Fda announcement","year":"2014"},{"issue":"8","key":"10.1016\/j.metabol.2014.07.017_bb0670","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/jc.2008-1019","article-title":"Approach to the human immunodeficiency virus-infected patient with lipodystrophy","volume":"93","author":"Brown","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0675","first-page":"134","article-title":"Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review","volume":"14","author":"Aberg","year":"2006","journal-title":"Top HIV Med"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0680","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1742-1241.2006.01267.x","article-title":"Insulin resistance and HIV infection: a review","volume":"61","author":"Aboud","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.metabol.2014.07.017_bb0685","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1293.2007.00488.x","article-title":"A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy","volume":"8","author":"Kohli","year":"2007","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.metabol.2014.07.017_bb0690","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0695","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0700","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial","volume":"143","author":"van Wijk","year":"2005","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.metabol.2014.07.017_bb0705","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/518005","article-title":"A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy","volume":"195","author":"Cavalcanti","year":"2007","journal-title":"J Infect Dis"},{"issue":"9407","key":"10.1016\/j.metabol.2014.07.017_bb0710","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.metabol.2014.07.017_bb0715","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/hct0904-254","article-title":"Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone","volume":"9","author":"Macallan","year":"2008","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.metabol.2014.07.017_bb0720","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-511X-6-27","article-title":"Are HIV positive patients resistant to statin therapy?","volume":"6","author":"Johns","year":"2007","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0725","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","article-title":"Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study","volume":"39","author":"Gerber","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0730","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-0028-1082048","article-title":"Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment","volume":"41","author":"Andreev","year":"2009","journal-title":"Horm Metab Res"},{"issue":"11","key":"10.1016\/j.metabol.2014.07.017_bb0735","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2006-1174","article-title":"Improved triglycerides and insulin sensitivity with 3months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia","volume":"91","author":"Hadigan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2014.07.017_bb0740","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/497273","article-title":"Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia","volume":"41","author":"Wohl","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.metabol.2014.07.017_bb0745","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-1293.2006.00399.x","article-title":"A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy","volume":"7","author":"Bickel","year":"2006","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.metabol.2014.07.017_bb0750","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QAI.0b013e31804a7f68","article-title":"Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12week induction and 24-week maintenance therapy","volume":"45","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.metabol.2014.07.017_bb0755","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1152\/japplphysiol.00845.2002","article-title":"Preferential loss of omental\u2013mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy","volume":"94","author":"He","year":"2003","journal-title":"J Appl Physiol"},{"issue":"2","key":"10.1016\/j.metabol.2014.07.017_bb0760","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.292.2.210","article-title":"Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial","volume":"292","author":"Koutkia","year":"2004","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.metabol.2014.07.017_bb0765","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/QAD.0b013e32830a5058","article-title":"Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation","volume":"22","author":"Falutz","year":"2008","journal-title":"AIDS"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:09:12Z","timestamp":1758427752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514002376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0026049514002376"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.07.017","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptin in congenital and HIV-associated lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}